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Heat shock factor 1 (HSF1) is the master regula-
tor of the heat shock response in eukaryotes,
a very highly conserved protective mechanism.
HSF1 function increases survival under a great
many pathophysiological conditions. How it
might be involved inmalignancy remains largely
unexplored. We report that eliminating HSF1
protects mice from tumors induced by muta-
tions of the RAS oncogene or a hot spot muta-
tion in the tumor suppressor p53. In cell culture,
HSF1 supports malignant transformation by or-
chestrating a network of core cellular functions
including proliferation, survival, protein syn-
thesis, and glucose metabolism. The striking
effects of HSF1 on oncogenic transformation
are not limited to mouse systems or tumor initi-
ation; human cancer lines of diverse origins
show much greater dependence on HSF1 func-
tion to maintain proliferation and survival than
their nontransformed counterparts. While it en-
hances organismal survival and longevity under
most circumstances, HSF1 has the opposite
effect in supporting the lethal phenomenon of
cancer.
INTRODUCTION
The heat shock response is one of the most ancient and
evolutionarily conserved protective mechanisms found in
nature. Environmental insults provoke a variety of adap-
tive physiological responses to help organisms cope
with specific stressors. The dramatic induction of heat
shock proteins (HSPs) is an important unifying component
of most of these responses, and this induction has proven
to be essential for survival under stressful conditions.
Work over the last three decades has revealed that the
major HSPs are molecular chaperones that guard against
‘‘illicit or promiscuous interactions’’ between other pro-
teins. Their basal expression facilitates normal proteinCell 1folding and guards the proteome from the dangers of
misfolding and aggregation. In the face of proteotoxic
stressors including heat, hypoxia/ischemia, free radicals,
ATP depletion, and acidosis, the importance of HSPs in
preventing the aggregation and promoting the refolding
of other proteins becomes acute. When misfolding ex-
ceeds a certain threshold, other HSPs disaggregate pro-
teins and refold them or divert them to the proteasome
for destruction (Whitesell and Lindquist, 2005).
Regulation of HSP expression is intricate, with multiple
layers of redundancy and feedback control, but a small
family of transcription factors called heat shock factors
(HSFs) are the primary regulators of stress-inducible ex-
pression in eukaryotic cells. The structure and function
of HSFs have been conserved for more than a billion
years. They bind consensus heat shock elements (HSEs)
within the promoter regions of HSP genes (Westerheide
andMorimoto, 2005), and this binding is critical to HSP in-
duction. Several HSFs are present in mammalian cells, but
HSF1 is clearly the dominant factor controlling cellular re-
sponses to stress. Deletion of Hsf1 in mammalian cells
allows normal basal expression of HSPs but completely
abrogates induction in response to heat shock and a vari-
ety of other stresses (Xiao et al., 1999). In mice and
Drosophila, HSF1 is dispensable for growth and survival
under controlled laboratory conditions but essential for
survival following stresses such as high temperature and
endotoxin challenge (Jedlicka et al., 1997; Xiao et al.,
1999). Hsf1-deficient mouse embryos suffer from defects
in placental development and are recovered from crosses
in lower numbers than expected by Mendelian segrega-
tion. Other than being 20% smaller than wild-type
mice, however, they display no overt organ system ab-
normalities and, in the absence of acute stress, live to
late adulthood (Xiao et al., 1999; A. Steele and S.L.,
unpublished data).
Although less well understood, the activities of HSF1
extend far beyond the classical induction of HSPs. In
yeast, HSF1 has now been shown to regulate up to 3%
of the genome and impact genes ranging in function
from energy production to signal transduction, from
small molecule transport to carbohydrate metabolism,
and from cytoskeletal organization to vesicular transport
(Hahn et al., 2004). Immunolocalization and chromatin30, 1005–1018, September 21, 2007 ª2007 Elsevier Inc. 1005
immunoprecipitation indicate that HSF1 binds to a simi-
larly broad array of non-HSP genes in Drosophila (West-
wood et al., 1991; Birch-Machin et al., 2005) and human
erythroleukemia cells (Trinklein et al., 2004).
The HSF1-mediated stress response and the activity of
specific HSPs have both been implicated in protecting or-
ganisms from a broad range of pathophysiological condi-
tions including thermal injury, ischemia/reperfusion, and
age-related neurodegeneration (Christians et al., 2002;
Westerheide and Morimoto, 2005). Intriguingly, in nema-
todes, HSF1 promotes longevity under stable laboratory
conditions (Hsu et al., 2003; Morley and Morimoto,
2004). Much less is known about the role of HSF1 in can-
cer. It has long been noted that HSP levels increase in
a wide range of tumor types (Jolly and Morimoto, 2000).
Many of the signaling pathways and transcription factors
that are frequently deranged in cancers display a striking
dependence on the chaperone machinery, especially
HSP90 (Whitesell and Lindquist, 2005). Moreover, HSF1
expression is elevated in human prostate carcinoma cell
lines (Tang et al., 2005). But whether the multifaceted
HSF1-mediated stress response plays a causal, sup-
portive, or inhibitory role in mammalian oncogenesis is
unknown.
On the one hand, given its prominent role in helping cells
cope with stressful insults, HSF1might promote oncogen-
esis by facilitating cellular adaptation to the malignant
lifestyle. On the other hand, given its general role in
enhancing longevity, HSF1 might assist organisms in
combating malignancy. To investigate these possibilities,
we used both whole-animal and cell-culture models in
which HSF1 expression could be disrupted by genetic
techniques. We find that HSF1 is a remarkably potent
modifier of tumor-free survival in whole animals. Further,
it modulates oncogenesis by coordinating a diverse array
of core cellular functions and supports the aberrant prolif-
eration and survival of human tumor cell lines carrying
a wide range of molecular genetic defects. As a very an-
cient adaptive mechanism, the HSF1-dependent stress
response has evolved to enhance survival in the face of
environmental challenges from without and disease
processes within such as ischemic injury and neurode-
generation. These broadly recognized beneficial effects,
however, contrast sharply with its lethal role in the phe-
nomenon of cancer that we now report.
RESULTS
HSF1 Deficiency Suppresses Chemical Skin
Carcinogenesis in Mice
To begin investigating the role of Hsf1 as a modifier of
tumorigenesis, we used a classical multistep chemical
skin carcinogenesis protocol. In this mouse model, so-
matic mutations are induced in epidermal cells by a single
topical application of the mutagen dimethylbenzanthra-
cene (DMBA). Tumor promotion is then achieved by re-
peated applications of the phorbol ester 12-O-tetradeca-
noylphorbol-13-acetate (TPA). Early on, the overwhelming1006 Cell 130, 1005–1018, September 21, 2007 ª2007 Elseviemajority of the resulting skin tumors are benign papillo-
mas. A small portion of these tumors spontaneously prog-
ress to become malignant squamous cell carcinomas,
which are invasive and sometimes metastatic (Yuspa,
1994). When Hsf1 wild-type mice (Hsf1+/+) and their Hsf1
null littermates (Hsf1/) were treated with DMBA and
TPA, no obvious skin damage or irritation was noticed in
either genotype after topical application of the chemicals.
There was, however, a striking difference in carcinogen-
induced tumorigenesis.
Hsf1/mice were far more resistant to tumor formation
than Hsf1+/+ mice (Figure 1A), and this difference was
manifested in several ways. First, the latency period be-
fore the development of any tumors was 5 weeks longer
in Hsf1/ mice than in Hsf1+/+ mice (Figure 1B). Second,
Hsf1/ mice exhibited a marked reduction in tumor inci-
dence (Hsf1+/+ 93.1% versus Hsf1/ 60.9% at week 24,
p = 0.0047, chi-square test) (Figure 1B). Third, they had
a much lower overall tumor burden. This applied both to
the number of tumors that arose (Figure 1C) and to the
size the tumors achieved (Figure 1D). Fourth, andmost im-
portantly, Hsf1/ mice survived much longer than their
wild-type counterparts (Figure 1E).
To further investigate the extraordinary resistance of
Hsf1/mice to carcinogen-induced tumorigenesis, an in-
dependent experiment was performed in which Hsf1/
mice and their wild-type littermates were treated with
a second mutagen, NMMG (N-methyl-N0-nitro-N-nitroso-
guanidine), at week 25 to promote tumor progression.
Once again, Hsf1/mice developed many fewer tumors.
They also had a very strong survival advantage over
Hsf1+/+ mice (see Figure S1A in the Supplemental Data
available with this article online). Thus, in sharp contrast
to the many circumstances under which Hsf1-deficient
organisms are at a survival disadvantage relative to wild-
type organisms, in survival after chemically induced skin
carcinogenesis they have a profound advantage.
Nature of Carcinogen-Induced Tumors
Although there was a large difference in the number of tu-
mors formed in theHsf1+/+ andHsf1/mice, the percent-
age of benign versus malignant tumors (papilloma versus
squamous cell carcinoma) was comparable (Figures S1C
and S1D). Next we asked if the tumors harboredmutations
in the H-Ras proto-oncogene. This gene is almost always
activated during chemical skin carcinogenesis. Further-
more, activating mutations of RAS occur in approximately
30%of all human cancers including skin cancers (Balmain
et al., 1984; Sebti and Adjei, 2004). Fourteen skin lesions
were randomly sampled in both genotypes. All harbored
activating mutations in H-Ras. Strikingly, these occurred
at positions that are known hot spots in human malignan-
cies (Table S1).
HSF1 Deficiency Suppresses Tumorigenesis
Driven by Mutant p53
To test the generality of the detrimental effects of HSF1
on tumor-free survival, we examined its impact on ther Inc.
Figure 1. HSF1 Deficiency Suppresses Chemical Skin Carcinogenesis
(A) Representative images of mouse skin tumors 25 weeks after topical DMBA application.
(B) Lower skin tumor incidence and longer incubation time in Hsf1/ mice (p < 0.0001, two-way ANOVA).
(C) Lower tumor burden in Hsf1/mice. The data are presented as the number of skin tumors per mouse (mean ± SE, p < 0.0001, two-way ANOVA).
(D) Smaller tumor volumes in Hsf1/ mice (the lines indicate geometric means; p = 0.0003, Mann Whitney test).
(E) The survival curves of Hsf1+/+ and Hsf1/mice following skin carcinogenesis (median survival: Hsf1+/+ 41 weeks; Hsf1/ undefined; p = 0.0073,
Logrank test).development of tumors in mice carrying a germline muta-
tion in the tumor suppressor p53, the most frequently mu-
tated gene in human cancers. We crossed mice heterozy-
gous for a clinically relevant hot spot mutation (p53R172H;
Olive et al., 2004) with Hsf1+/ mice. Three genotypes,
all heterozygous for p53 R172H, were examined: (1)
Hsf1+/+, (2) Hsf1+/, and (3) Hsf1/. Mice were allowed
to age with no intervention and were monitored for tumor
formation and overall survival. Moribund mice were sacri-
ficed and subjected to full necropsy to detect potential
tumor formation at the gross and microscopic levels in
all major tissues and organs.
Tumor-free survival was dramatically prolonged in
Hsf1/ mice carrying a mutant p53 allele (Figure 2A).
Strikingly, even Hsf1+/ mice survived longer than the
Hsf1+/+ mice, indicating a dosage-dependent effect of
HSF1. Median survivals were 427 days for Hsf1+/+ mice,
470 days for Hsf1+/, and >622 days for Hsf1/ mice.
Thus, as with the skin carcinogenesis model, Hsf1-defi-
cient mice had a surprising and profound survival advan-
tage compared to wild-type animals.
Nature of p53 Mutant Tumors
Histopathological review revealed that both Hsf1+/+ and
Hsf1+/ mice produced a broad spectrum of tumor types
when carrying the p53R172H hot spot mutation. TheseCell 1included sarcomas, lymphomas, and carcinomas (Fig-
ure 2B). Intriguingly, in this model, compromise of Hsf1
function appeared to alter the distribution of tumor types.
Hsf1+/mice had an increase in carcinoma frequency and
a decrease in sarcoma frequency compared to Hsf1+/+
mice (Figure 2C). Note, however, that changes in the
tumor spectrum of Hsf1/ mice could not be determined
because so very few mice of this genotype developed
tumors.
Hsf1 Status Does Not Alter Intrinsic Cell
Growth Rates
To pursue observationsmade inmice at a cellular andmo-
lecular level, we examined the effect ofHsf1 status on sev-
eral classical parameters of neoplastic transformation in
cell culture. First, we examined freshly isolated mouse
embryonic fibroblasts (MEFs). Hsf1+/+ and Hsf1/ cells
had comparable growth rates in vitro (data not shown).
Moreover, staining cells for DNA content followed by
flow cytometry revealed similar cell-cycle profiles in both
genotypes (Figure S1B). Thus, the dramatic resistance
of Hsf1/ mice to tumor formation was not due to an in-
trinsic defect in cell proliferation or cell-cycle progres-
sion. Next, we used MEFs that had been previously im-
mortalized, but not transformed, by stable expression of
the E6 and E7 proteins of human papilloma virus (HPV)30, 1005–1018, September 21, 2007 ª2007 Elsevier Inc. 1007
Figure 2. HSF1 Deficiency Suppresses
Tumorigenesis Driven by Mutant p53
(A) Tumor-free survival curves of p53R172H
knockin mice (Hsf1+/+ versus Hsf1/, p =
0.0001; Hsf1+/ versus Hsf1/, p = 0.0185;
Hsf1+/+ versus Hsf1+/, p = 0.0387; Logrank
test).
(B) Representative micrographs of tumors
(scale bars, 160 mm). (Ba) Carcinoma, (Bb) lym-
phoma, (Bc) soft tissue sarcoma, (Bd) teratoma
(A, adipose; B, bone; M, muscle; RE, respira-
tory epithelium).
(C) Tumor spectra of Hsf1+/+ and Hsf1+/ mice
(Hsf1+/+, n = 15; Hsf1+/, n = 10).1008 Cell 130, 1005–1018, September 21, 2007 ª2007 Elsevier Inc.
(McMillan et al., 1998) and transformed themwith a variety
of oncogenes.
HSF1 Enables Cellular Transformation Initiated
by Oncogenic RAS
To directly investigate susceptibility to transformation by
RAS, MEFs were transduced with retroviruses encoding
green fluorescent protein (GFP), mouse Hsf1, or onco-
genic H-RASV12D, a RASmutation commonly found in hu-
man cancers. After several weeks in culture, cells were
fixed and stained to visualize the transformed foci that
had arisen as a consequence of the classic RAS-mediated
loss of contact inhibition of growth.
Transduction with H-RASV12D induced high rates of fo-
cus formation in wild-type cells, but such foci were rare
in cells derived from mice carrying the germline deletion
(Hsf1/ cells; Figure 3A and Figure S2A). Cells from
both the abundant Hsf1+/+ foci and the rare Hsf1/ foci
were fully transformed as measured by soft agar cloning
and tumor formation following subcutaneous injection
into nude mice (data not shown). As expected, transduc-
tion with virus encoding GFP did not induce focus forma-
tion. Importantly, focus formation was also not observed
with Hsf1 overexpression (Figure 3A and Figure S2A).
Thus, by this criterion, Hsf1 acts as a powerful modifier
of tumorigenesis rather than as an oncogene per se.
Reduced transformation ofHsf1/ cells was not due to
an intrinsic growth defect, nor was it due to reduced viral
transduction efficiency. Both immortalized cell types dis-
played comparable saturation densities (Figure 3A,
mean ± SD, Hsf1+/+ 2832 ± 267 nuclei per field versus
Hsf1/ 3411 ± 275, n = 5, p = 0.0096) and proliferation
characteristics (Figure S4). If anything, Hsf1/ MEFs
displayed slightly greater gene transfer efficiencies as
measured by flow cytometry after transduction with GFP-
encoding retrovirus (mean ± SD, Hsf1+/+, 9.0% ± 0.6%
positive versus Hsf1/, 12.7% ± 1.4% positive, n = 4,
p = 0.003).
To control for the unlikely possibility that reduced trans-
formation in Hsf1/ MEFs was due to a potent but un-
known polymorphism that happened to be closely linked
to the HSF1 gene, we took advantage of short hairpin
RNA interference (shRNAi) technology. Independent sta-
ble Hsf1 knockdown cell lines were generated from
Hsf1+/+ MEFs using five different lentiviral vectors, each
encoding a distinct Hsf1-targeted sequence. Two knock-
down lines with differential gene silencing, C2 and C3,
were chosen for further experiments. C3 cells, in which
HSF1 levels were only partially reduced, behaved like
wild-type cells in the RAS transformation assay. Isogenic
C2 cells, in which HSF1 levels were dramatically reduced,
behaved like Hsf1/ MEFs from the germline knockout
(Figures S3A–S3C).
HSF1 Enables Cellular Transformation
by the Proto-Oncogene PDGF-B
To determine whether transformation-permissive effects
of HSF1 at the cellular level extend beyond activatingCell 1mutations of H-RAS, we tested another potent proto-
oncogene: platelet-derived growth factor B (PDGF-B).
As withRAS,Hsf1/MEFs displayed dramatic resistance
to focus formation induced by PDGF-B compared to
Hsf1+/+ cells (Figure 3B and Figure S2B). These findings,
too, were confirmed with shRNAi experiments (Figures
S3D–S3F). Thus, HSF1 also exerts a marked effect on
cellular transformation initiated by overexpression of
PDGF-B, an oncoprotein that activates multiple signaling
cascades in addition to the RAS/MAPK pathway.
HSF1 Enhances Proliferation and Survival
in Response to Diverse Oncogenic Stimuli
Neoplastic stimuli can increase the rates of cell prolifera-
tion, cell survival, or both. To determine which of these
processes is influenced by HSF1, immortalized Hsf1+/+
and Hsf1/ MEFs were transduced with retroviruses en-
coding GFP or several mechanistically distinct onco-
genes. Retroviral transduction of H-RAS and PDGF-B
drove a marked increase in cell number in Hsf1+/+ cells,
but not in Hsf1/ cells (Figure 3C). This was due to in-
creased proliferation ofHsf1+/+ cells rather than increased
death in Hsf1/ cells (Figure 3E).
Unlike RAS and PDGF-B, which act as mitogenic signal
transducers, c-MYC and LTA act primarily as regulators of
cell-cycle progression and might not be expected to dra-
matically increase proliferation in these already-immortal-
ized cell lines. Indeed, c-MYC and SV40 Large T Antigen
(LTA) did not significantly increase cell accumulation
(Figure 3D) or induce focus formation (data not shown).
LTA and c-MYC can, however, predispose cells to apo-
ptosis (Evan et al., 1992; Yin et al., 1997). Indeed, in
contrast with RAS and PDGF, c-MYC and LTA sharply in-
creased cell death in Hsf1/ cultures, but not in Hsf1+/+
cultures (Figure 3E). Thus, depending upon the nature of
the oncogenic stimuli involved, HSF1 enables oncogenic
transformation in at least two ways, by permitting in-
creased cell proliferation and/or by decreasing cell death.
HSF1 Modulates Signal Transduction
The ability to sustain dysregulated signaling is crucial to
human cancers. In light of our observation that Hsf1/
MEFs are resistant to RAS-driven transformation, we
sampled downstream effectors in the RAS/MAPK signal-
ing pathways. HSF1 deficiency caused a marked reduc-
tion in the levels of kinase suppressor of RAS 1 (KSR1)
protein, both in Hsf1/ MEFs and in shRNAi knockdown
lines (Figure 4A). Furthermore, activation of the down-
stream effector, ERK, was blunted in Hsf1/ MEFs
following serum stimulation (Figure 4B).
We also asked whether Hsf1 affects the G protein-
coupled receptor (GPCR) pathway, which increases
cAMP levels, drives PKA activation, and is implicated in
many human cancers (Bossis et al., 2004). A marked re-
duction in the phosphorylation of endogenous PKA sub-
strates was observed in cells with germline Hsf1 deletion
(Figure 4C). shRNAi-mediated Hsf1 knockdown in wild-
type cells produced a similar effect. (In this case, dosage30, 1005–1018, September 21, 2007 ª2007 Elsevier Inc. 1009
Figure 3. HSF1 Enables Cellular Transformation Initiated by Oncogenic RAS and PDGF-B
(A) Hsf1/ MEFs are relatively resistant to focus formation driven by oncogenic H-RASV12D. Immortalized MEFs were plated and transduced with
retroviruses encoding the genes indicated. Foci were fixed and visualized by dye staining. The number of foci per well was quantified as shown in
Figure S2. All experiments were repeated once with similar results.
(B) Hsf1/ MEFs are relatively resistant to focus formation driven by the proto-oncogene PDGF-B.
(C) Hsf1/ MEFs are refractory to proliferation driven by oncogenic RAS and PDGF-B. Equal numbers of immortalized Hsf1+/+ and Hsf1/ MEFs
were transduced with retroviruses encoding GFP, H-RASV12D, or PDGF-B. The cells were fixed on the indicated days and the number of cells per
well determined by fluorescent DNA staining. Relative cell number was calculated by normalizing the values against the GFP-transduced group at
each time point (mean ± SD, n = 5, ***p < 0.001, two-way ANOVA).
(D) Expression of c-MYC and LTA does not drive marked proliferation in immortalized Hsf1+/+ and Hsf1/ MEFs.
(E) Hsf1/ MEFs show no enhanced survival in response to RAS and PDGF/B expression but reduced survival in response to c-MYC and LTA ex-
pression. Viability of immortalized Hsf1+/+ and Hsf1/ MEFs was determined by flow cytometry 36 hr after transduction. The data are presented as
percent nonviable cells (mean ± SD, n = 5, *p < 0.05; ***p < 0.001, Student’s t test).sensitivity was apparent.) These differences in PKA activ-
ity were verified by directly measuring the phosphorylation
of a standard peptide substrate. Lysates from Hsf1/
cells demonstrated less than half the PKA activity of ly-
sates from Hsf1+/+ cells (mean ± SD, Hsf1+/+ 2452 ± 4511010 Cell 130, 1005–1018, September 21, 2007 ª2007 ElsevieversusHsf1/ 917 ± 100, n = 2, p < 0.05) (Figure 4D). Hav-
ing found that HSF1 modulates at least two classical on-
cogenic signaling pathways, we asked if it affects other
crucial, but more recently recognized, cancer-related pro-
cesses: ribosomal biogenesis and translation control.r Inc.
Figure 4. HSF1 Modulates Signal Transduction
(A)Hsf1/ and C2-transducedMEFs show remarkably decreased expression of KSR1 protein by immunoblotting. Ponceau red staining was used to
confirm equal protein loading.
(B) Hsf1/ MEFs display blunted ERK activation in response to serum stimulation. Cells were stimulated with 20% FBS for the periods of time in-
dicated, then fixed and stained with phospho-ERK1/2 antibody (green) and the DNA stain TO-PRO-3 iodide (red), which was used to normalize
for relative cell number. The plate was scanned, and data are presented as relative phospho-ERK1/2 level by setting values at 0 min as 100%
(mean ± SD, n = 5, **p < 0.01; ***p < 0.001; two-way ANOVA).
(C) Hsf1/ and Hsf1 knockdown cells showmarkedly reduced phosphorylation of endogenous PKA substrates. Equal amounts of total protein were
loaded and probed with antibodies recognizing phospho-(Ser/Thr) PKA substrate, HSF1, and GAPDH, respectively.
(D) Hsf1/MEFs possess lower PKA activity. The PKA activity in lysates prepared from Hsf1+/+ and Hsf1/MEFs was measured using the classical
substrate Kemptide. Reaction mixtures were fractionated by agarose gel electrophoresis to visualize the extent of substrate phosphorylation. PKA,
recombinant PKA as positive control. NC, peptide substrate only without lysate or recombinant PKA. The relative amount of phosphorylated peptide
in each lane was quantitated by fluorometry.HSF1 Modulates the Translation Machinery
The dysregulated growth of cancer cells requires growth
factor independence in the control of ribosome biogenesis
and protein translation. To reveal a potential role for HSF1
in this process, we culturedMEFs under growth factor-de-
pleted conditions—that is, serum starvation. HSF1 status
caused no difference in the levels of eIF4E, an mRNA cap-
binding protein, b-actin, or glyceraldehyde-3-phosphate
dehydrogenase (GAPDH). However, HSF1-deficient
MEFs consistently had reduced levels of the three ribo-
somal subunits tested, L26RP, L28RP, and S6RP,
whether they were deficient from germline knockout or
from an shRNAi (Figures 5A and 5B). Furthermore, much
lower levels of phosphorylated ribosomal protein S6 ki-
nase (p70 S6K), a potent regulator of translational activ-
ity, were observed in Hsf1-deficient cells compared to
wild-type cells (Figures 5A and 5B). Importantly, in bothCell 1germline-deleted and shRNAi knockdown cells, compara-
ble levels of these ribosomal proteins were restored when
the cells were returned to culture in serum-repletemedium
(Figures 5A and 5B). Thus, HSF1 deficiency enforces
tighter growth factor dependency on the translational
machinery.
Inhibition of mTOR function by rapamycin impairs pro-
tein translation and reduces cell size. Eliminating its down-
stream effector, p70 S6K, recapitulates this phenotype
(Fingar et al., 2002). The lower levels of p70 S6K phos-
phorylation in Hsf1-deficient cells, together with the
smaller size of Hsf1/ mice (Xiao et al., 1999; and data
not shown) led us to ask if individual cells derived from
Hsf1/ mice are smaller than Hsf1+/+ cells. Indeed, the
mean cell volume (pL) of Hsf1/ MEFs was 20% less
than that of Hsf1+/+ MEFs (1925 ± 49 versus 2401 ± 184,
mean ± SD, n = 3, p < 0.05). This suggested that the30, 1005–1018, September 21, 2007 ª2007 Elsevier Inc. 1011
Figure 5. HSF1 Modulates Translation Machinery
(A and B) HSF1 maintains p70 S6K phosphorylation and ribosomal protein expression during serum starvation. Cells were first serum starved for
2 days, then either stimulated with 20% FBS overnight or maintained under serum-free conditions.
(C)Hsf1/MEFs are more sensitive to the proliferation-inhibitory effect of rapamycin. Cells were exposed to a series of rapamycin concentrations as
indicated for 5 days. After fixation, the relative number of cells in each well was determined by DNA staining. Data are presented as percent control by
normalizing the values of rapamycin-treated wells against those of solvent-treated wells (mean ± SD, n = 5, **p < 0.01, two-way ANOVA).
(D) Hsf1/ MEFs are more susceptible to cell-cycle arrest induced by rapamycin. Cells were treated with either methanol vehicle or rapamycin
(100 nM) for 24 hr. Cell-cycle distribution was determined by flow cytometry. Data are presented as percent cells in each phase of the cell cycle
(mean ± SD, n = 3, ***p < 0.001, two-way ANOVA).mTOR pathway might be affected by Hsf1 status. Indeed,
Hsf1/ cells were significantly more sensitive than Hsf1+/+
cells to rapamycin-induced growth inhibition (Figure 5C
and Figure S5A). The hypersensitivity of Hsf1/ cells
was not due to increased cell death (data not shown).
Instead, rapamycin caused the same type of cell-cycle
arrest in G1 typical of mTOR inhibition, but it was more
profound inHsf1/ than inHsf1+/+ cells (Figure 5D). Nota-
bly, rapamycin neither induced a heat shock response nor
impaired it (Figure S5B). Thus, independently of a classic
proteotoxic stress response, HSF1 maintains the activity
of the translation machinery and permits continued cell-
cycle progression in immortalized but nontransformed
cells under growth factor-reduced conditions in a manner1012 Cell 130, 1005–1018, September 21, 2007 ª2007 Elseviethat likely involves the role of mTOR in regulating protein
translation.
HSF1 Modulates Glucose Metabolism
Unlike normal cells, virtually all cancer cells preferentially
catabolize glucose by glycolysis, even under normoxic
conditions, and thereby produce high levels of lactic acid
(Bissell et al., 1976; Gatenby and Gillies, 2004). Recent ev-
idence indicates that increased glycolysis is a conse-
quence of oncogenic transformation and is advantageous
to tumor growth and survival (Fantin et al., 2006; Matoba
et al., 2006). To determine whether Hsf1 status alters glu-
cose metabolism, we first examined glucose uptake,
which is almost universally increased in cancers.r Inc.
Figure 6. HSF1 Modulates Glucose Metabolism
(A and B) HSF1 regulates glucose uptake. Cells were incubated in medium containing either PBS (dotted lines) or 100 mM 2-NBDG (solid lines)
overnight. The extent of glucose uptake was measured by flow cytometry. Data are presented as frequency histograms of relative tracer uptake.
(A) depicts Hsf1+/+ (red line) and Hsf1/ MEFs (blue line). (B) depicts C2 (blue line)- and C3 (red line)-transduced MEFs. The mean fluorescence in-
tensity of each cell population is indicated (mean ±SD, n = 5,Hsf1+/+ versusHsf1/ 2-NBDGp< 0.0001; C3 versus C2 2-NBDG p< 0.0001, Student’s
t test).
(C and D) Hsf1/ MEFs are relatively resistant to glucose deprivation. Cells were incubated with either glucose-replete or -reduced medium for
4 days. The number and viability of cells in each well were determined by flow cytometry. Data are presented as relative cell numbers and percent
nonviable cells (mean ± SD, n = 5, ***p < 0.001, two-way ANOVA).Hsf1+/+ andHsf1/MEFswere cultured overnight in the
presence of a fluorescent, noncleavable glucose analog,
2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]-2-deoxy-
glucose (2-NBDG).Hsf1/MEFs accumulated much less
2-NBDG than did Hsf1+/+ cells (Figure 6A). Hsf1 knock-
down MEFs exhibited the same trend, although greater
variability was observed, as expected in the heteroge-
neous population of knockdown cells (Figure 6B).
Tumor cells, which utilize glucose at a much higher rate
than normal cells, are generally more sensitive to glucose
deprivation. We asked if Hsf1/ cells are less addicted to
glucose and less sensitive to its deprivation. Culturing
Hsf1+/+ MEFs for 4 days in glucose-reduced medium led
to a drastic decrease in total cell number and cell viability
relative to cells cultured in standard high-glucose medium
(Figures 6C and 6D). Hsf1/ MEFs tolerated low glucose
conditions much better. Thus, HSF1 deficiency leads to
reduced dependence on glucose to support cellular en-
ergy needs and/or more efficient use of the sugar. Two
other findings support this hypothesis. First, the nonmeta-
bolizable glucose analog 2-deoxy-glucose (2-DG), which
competes with glucose for the key glycolytic enzymeCell 1phosphohexose isomerase, killed Hsf1+/+ cells more effi-
ciently than Hsf1/ cells (Figure S6A). Second, under
glucose-replete conditions, Hsf1/ and shRNAi C2 cells
generated significantly less lactate and possessed lower
lactate dehydrogenase (LDH) activity than Hsf1+/+ cells
(Figures S6B and S6C). Thus, the resistance of Hsf1-defi-
cient cells to malignant transformation that we have dem-
onstrated is associated with a pattern of basal glucose
metabolism that could make it more difficult for them to
undergo the glycolytic shift characteristic of cancers.
HSF1 Maintains the Transformed Phenotype
Having established in whole mice and cultured mouse
cells that HSF1 is required in multifaceted ways for the ini-
tiation of transformation, we asked if it was also required
for the maintenance of transformed phenotypes in estab-
lished oncogenic cell lines and, at the same time, whether
it was relevant to human cancers. We chose human lines
of varying malignant potential, lines created in the labora-
tory with known oncogenes and lines derived from natu-
rally occurring tumors with a diversity of histopathological
origins and a broad spectrum of molecular genetic30, 1005–1018, September 21, 2007 ª2007 Elsevier Inc. 1013
Figure 7. HSF1 Is Required for Maintenance of the Transformed Phenotype
(A) ShRNA constructs exhibit differential HSF1-targeting efficacy. 293T cells were transfected with equal amounts of the indicated shRNA plasmid
DNAs, and MCF-7 cells were transduced with the same shRNA constructs but packaged as lentiviral supernatants. Cells were harvested for immu-
noblotting after 3 days of puromycin selection.
(B) The effect of HSF1 compromise on cell growth and survival correlates with malignant state. Cells were plated in 96-well format and transduced
with viral supernatants as indicated. Viable cell number in eachwell wasmeasured 4 days after viral transduction. Data are presented as relative viable
cell number by normalizing the values of each transduction group against those of GFP shRNA-transduced wells (mean ± SD, n = 5, *p < 0.05,
**p < 0.01, ***p < 0.001, two-way ANOVA).
(C) Compromise of HSF1 impairs the growth and survival of established human breast cancer cells (mean ± SD, n = 5, *p < 0.05, **p < 0.01, ***p <
0.001, two-way ANOVA).
(D) Compromise of HSF1 impairs the growth and survival of human cancer cells derived from diverse histological origins (mean ± SD, n = 5, *p < 0.05,
**p < 0.01, ***p < 0.001, two-way ANOVA). All experiments were repeated at least once with similar results.abnormalities. To modulate HSF1 expression, we evalu-
ated three independent human HSF1-targeted shRNAi
constructs, hA8, hA9, and hA6, and two control constructs
(a GFP-targeted shRNAi and an shRNAi with no known
homology within the human genome), all of the same in-
fectious titers (Figure S8). Only the three HSF1-targeted
vectors lowered HSF1 levels (Figure 7A); the most effica-
cious, hA6 and hA9, were selected for further analysis.
We first examined three breast cell lines representing
progressively more oncogenic states (Figure 7B): (1) pri-
mary human mammary epithelial (PHME) cells; (2) human
mammary epithelial (HME) cells made immortal, but non-
tumorigenic, by expression of hTERT (telomerase); and
(3) HME cells rendered fully transformed and tumorigenic
by introduction of LTA and H-RAS in addition to hTERT
(HMLER) (Elenbaas et al., 2001). PHME cells were little af-
fected by transduction with HSF1-targeted constructs.
Tumorigenic HMLER cells were strongly affected. Im-
mortalized, but nontumorigenic, cells (HME) were inter-
mediate in sensitivity, suggesting a correlation between
oncogenic state and HSF1 dependence (Figure 7B).1014 Cell 130, 1005–1018, September 21, 2007 ª2007 ElsevieNext we examined a diverse collection of breast cell
lines derived fromspontaneous human tumors (Figure 7C).
The lines varied with regard to p53 status, carrying wild-
type (MCF-7) or various mutant alleles (BT-474, MDA-
MB-231, and T47D) (International Agency for Research
on Cancer TP53 Database) and with regard to HER2 over-
expression, estrogen sensitivity, and metastatic potential
(MD Anderson Breast Cancer Cell Line Database). All
were strongly affected by both of the HSF1-inhibitory hair-
pins; none was affected by the control hairpins.
Finally, we examined malignant cells of diverse histo-
logical origins either derived from human tumors (HeLa
[cervix], PC-3 [prostate], and S462 and 90-8 [peripheral
nerve sheath]) or derived by in vitro transformation (293T
[kidney]). All were strongly inhibited by HSF1 knockdown
(Figure 7D). Where a difference in sensitivity to the two tar-
geting hairpins was observed, it was always the hairpin
that inhibited HSF1 expression the most severely (hA6;
Figure 7A) that had the stronger effect (Figures 7B and
7C). This strong correlation between the extent of HSF1 in-
hibition and phenotypic effects, together with the fact thatr Inc.
similar results were obtainedwith independent human and
mouse targeting sequences and with a mouse germline
knockout, argue strongly against ‘‘off-target’’ factors be-
ing responsible for these effects. Note also that the hair-
pins had no effect on normal diploid human fibroblasts
(WI-38; Figure 7D). Therefore, we conclude that, in addi-
tion to its enabling role in tumor initiation, HSF1 function
helps tomaintain the growth and survival of human cancer
cells with diverse underlying malignant defects.
DISCUSSION
Modulation of Oncogenesis by HSF1
As master regulator of the heat shock response, HSF1
enhances organismal survival and longevity in the face of
environmental challenges. In sharp contrast to its widely
appreciated beneficial effects, we now report that HSF1
can act to the detriment of organisms by supportingmalig-
nant transformation. Inmice,HSF1deficiency dramatically
limited spontaneous tumor formation initiated by a com-
mon, dominant-negative mutation of the p53 tumor sup-
pressor gene. It had a similar effect on chemical-induced
skin carcinogenesis associated with activating mutations
of the H-Ras proto-oncogene. The reduced incidence of
tumors in these animals, and their associated effects on
long-term survival, cannot be due to an effect of HSF1 on
mutation rates. HSF1 deficiency rendered cultured cells
highly refractory to transformation initiated by mutated
H-RAS and byPDGF-B overexpression. Most importantly,
the depletion of HSF1 in diverse previously established hu-
man cancer cell lines strongly impaired their growth and
survival while having little effect on normal cells.
Tumor cells undergo a drastic shift of intracellular milieu
during transformation. Gross alterations in signal trans-
duction, energy production, and themetabolism of nucleic
acids and protein are inevitable. In addition, cells within
a tumor mass are frequently exposed to harsh and rapidly
changing microenvironments that include such stressors
as hypoxia, acidosis, nutrient deprivation, and immune at-
tacks from the host. To survive and prosper, like organ-
isms living in the wild, tumor cells within a host must be
able to adapt effectively. Our data indicate that HSF1,
the master regulator of one of the most ancient and evolu-
tionarily conserved adaptive mechanisms, plays a promi-
nent role in enabling cells to accommodate such drastic
alterations, survive initial oncogenic stresses, and suc-
cessfully adapt to the malignant state. In this setting,
HSF1 function strongly reduces life span of the host.
Congruent with our findings, expression of the onco-
genes heregulin beta1 andRas has recently been reported
to activate HSF1. This activation protects such cells
against apoptosis and enables anchorage-independent
growth (Khaleque et al., 2005; Stanhill et al., 2006). During
the preparation of thismanuscript, another group reported
that HSF1 deficiency alters the spectrum of tumors arising
in p53 knockoutmice (Min et al., 2007). In contrast with our
findings, however, they found no significant effect either
on overall tumor incidence or on tumor-free survival.CellSeveral factors may account for this major discrepancy.
First, Min et al. used a different transgenic strategy to
knock out Hsf1, which resulted in unanticipated recombi-
nation events and only deleted the second exon of the
gene. Although wild-type HSF1 protein was not detected,
a truncated Hsf1 message was produced whose biologi-
cal consequences are unknown (Zhang et al., 2002). The
knockout mouse strain used to generate our data
expresses no Hsf1 message. Furthermore, to address
potential artifacts of transgenesis, our key findings using
Hsf1 knockout cells were confirmed using a variety of in-
dependent mouse and human shRNAi constructs. Sec-
ond, Min et al. evaluated the effects of HSF1 deficiency
in a p53 null mouse model while we looked at a clinically
relevant p53 missense mutation. Missense mutations in
the p53 DNA-binding domain are the most clinically rele-
vant lesions and have been reported in more than 50 dif-
ferent types of human cancer. Though complete deletions
are commonly associated with human malignancy for
other tumor suppressor genes, they occur rarely for p53,
and individuals with germline homozygous deletions are
unknown, raising questions as to the relevance of homo-
zygous p53 deletion as a cancer model (Olive et al.,
2004). Perhaps most importantly, we avoided model-
specific limitations by examining a variety of mechanisti-
cally distinct oncogenic stimuli other than p53 alteration
and demonstrated consistent effects in whole animals,
mouse cell cultures, and diverse human cancer cell lines.
Given these considerations, we believe our findings cap-
ture the role of HSF1 in oncogenesis on a broader, more
biologically and clinically relevant level.
Given the global nature of the alterations in cellular
physiology that occur during malignancy, rather than
deeply interrogating individual pathways, we pursued
a broad survey of potential mechanisms whereby HSF1
might modify tumorigenesis. We found moderate but
highly significant and readily detectable effects of HSF1
on a broad array of cellular functions, all of which play
a role in successful malignant transformation. First, de-
pending on the nature of the oncogenic stimulus, HSF1
enhances cell proliferation and/or survival. Second,
HSF1 modulates both of the major cancer-promoting sig-
nal transduction cascades that we tested, the RAS/MAPK
and cAMP/PKA pathways, and likely affects many more.
Third, HSF1 maintains efficient ribosomal biogenesis
and p70 S6K activation under growth factor-limited condi-
tions, which are particularly relevant to malignant states.
Lastly, HSF1 promotes glycolysis, a key metabolic path-
way for tumor growth and survival.
Our data indicate that HSF1 itself does not act as a clas-
sic oncogene or tumor suppressor. Neither enforced over-
expression nor knockout directly drives transformation.
Instead, HSF1 orchestrates a broad network of cellular
functions that act globally to support tumorigenesis
(Figure S9). Individually, any one of these effects might
have only a modest influence on malignant transforma-
tion. We suggest that the profound effects of HSF1 on tu-
mor initiation and transformation are due to their acting in130, 1005–1018, September 21, 2007 ª2007 Elsevier Inc. 1015
concert with each other and, indeed, with yet other mech-
anisms still to be discovered.
As a therapeutically relevant extension to our findings
on tumor initiation, we find that HSF1 also promotes can-
cer cell maintenance. Hsf1 knockout is not lethal, or even
detrimental to normal life span, in mice. Not surprisingly,
we find that HSF1 knockdown has a minimal effect on
the proliferation/survival of normal primary human cells
in culture. In marked contrast, compromise of HSF1 pro-
foundly impaired a wide variety of established human ma-
lignant as well as premalignant cell lines without relation-
ship to the diversity of their known underlying molecular
genetic defects.
Coupling Cellular Physiology to Environmental
Contingency by HSF1
The induction of HSPs by HSF1 can potentiate oncogen-
esis in a variety of ways. For example, HSP90 chaperones
many signal transducers, and certain oncoproteins are
particularly dependent upon it (Whitesell and Lindquist,
2005). Further, HSP70 and other chaperones interface
with the apoptotic machinery with important functional
consequences (Jolly and Morimoto, 2000). It is essential
to realize, however, that the effects of HSF1 extend far
beyond HSP induction.
Befitting a survival factor highly conserved for more
than 1 billion years and broadly deployed to combat
a wide variety of physiologically distinct toxicities, HSF1
is emerging as the coordinator of an extensive array of cel-
lular pathways at a system-wide level. For example, heat
stress activates the RAS/MAPK pathway in an HSF1-
dependent manner (Mivechi and Giaccia, 1995). Given
that intracellular cAMP levels rise upon heat stress and
the cAMP/PKA pathway negatively regulates HSF1 (Fer-
guson et al., 2005; Sawaji et al., 1999), crosstalk between
the cAMP/PKA pathways and other HSF1-mediated re-
sponse pathways seems almost certain. In yeast, HSF1
regulates 3% of the genome and occupies the promoter
regions of a wide variety of genes, including those for sev-
eral key glycolytic enzymes (Hahn et al., 2004). It appears
to regulate a similarly broad spectrum of genes in Dro-
sophila and man (Westwood et al., 1991; Birch-Machin
et al., 2005; Trinklein et al., 2004). Our data indicate the
involvement of HSF1 in regulating translation, ribosome
biogenesis, and glucose metabolism in mammalian cells.
For this emerging, system-wide regulation of growth and
survival pathways by HSF1, our work establishes a vital
functional consequence in oncogenesis.
Balancing Aging, Longevity, and Cancer Risk
Strikingly, our data now make it clear that HSF1 plays op-
posite roles in the complex diseases that plague aging
populations. It powerfully potentiates the development
of cancers. But it has also been implicated in protection
against ischemia/reperfusion injury, neurodegenerative
disorders, and other broad-ranging physiological pro-
cesses affecting life span, such as aging and senescence
(Auluck et al., 2005; Cohen et al., 2006; Gutsmann-Conrad1016 Cell 130, 1005–1018, September 21, 2007 ª2007 Elsevieret al., 1998; Hsu et al., 2003; Morley and Morimoto, 2004).
In aging cells and organisms, alterations in energy metab-
olism, signal transduction, and protein homeostasis are
accompanied by blunting of the stress response, ulti-
mately leading to compromised viability.
Such an astonishing duality for the effects of HSF1 mir-
rors the surprising double-edged roles recently reported
for the tumor suppressors p53 and p16INK4a. On the one
hand, expression of p53 or p16INK4a shortens life span
by accelerating cellular senescence and limiting the re-
generative capacity of stem and progenitor cells; on the
other hand, their activities extend life span by suppressing
the emergence of life-threatening cancers (Beausejour
and Campisi, 2006; Tyner et al., 2002). Our findings estab-
lish that an even more ancient survival factor, HSF1, has
a similar duality, in reverse: its normal functions extend
life span but in the case of cancer have a gravely deleteri-
ous impact on organismal survival. At a fundamental level,
the ability of HSF1 to enable lethal malignancies is an un-
fortunate legacy of its ancient role in enhancing the sur-
vival of normal cells exposed to diverse acute and chronic
stresses.
Our findings also have important therapeutic implica-
tions. An expanding array of small, drug-like compounds
are becoming available with potent HSF1-modulating ac-
tivity in cells and whole organisms. Therapeutic induction
of the HSF1-mediated stress response by noncytotoxic
exposure to agents such as HSP90 inhibitors and celas-
troloids is being explored in hypoxic-ischemic injury and
protein misfolding disorders such as Huntington’s and
Parkinson’s disease (Lu et al., 2002; Wang et al., 2005).
Whether the therapeutic activation of HSF1 would in-
crease the likelihood of oncogenic transformation is un-
known, but it seems imperative to determine. Conversely,
based on our findings with human cell lines, inhibiting
HSF1 activation could provide a multifaceted and broadly
effective cancer chemopreventive as well as chemothera-
peutic strategy but might accelerate neurodegenerative
processes and aging. A profound dichotomy holds true
for other centrally poised drug targets such as the protea-
some, whose inhibition is associated with promising anti-
cancer activity in certain malignancies (Richardson et al.,
2006) but in some situations might exacerbate neurode-
generative processes (McNaught et al., 2004). Using com-
pounds that do not cross the blood-brain barrier is just one
of many possible strategies to maximize benefits and re-
duce risks. We have much to learn about how the ancient
adaptive function of HSF1 operates in the maze-like inter-
face between genotype and environment to modify malig-
nancy and other complex ‘‘diseases of civilization.’’ At the




Hsf1+/ mice (BALB/c 3 129SvEV), a gift from Ivor J. Benjamin, were
intercrossed. DMBA (Sigma) (100 mg) dissolved in acetone wasInc.
applied topically to each mouse. One week later, 20 mg of TPA
(Sigma) was applied to each mouse twice a week for 24 weeks.
Skin tumor formation was monitored weekly, and tumor dimensions
were measured by caliper. The tumor volume is calculated as
[(width)2 3 length] O 2.
Tumorigenesis Study of p53R172H Mice
p53R172H/+ mice (129S4/SvJae), a gift from Tyler Jacks, were crossed
with Hsf1+/mice. Moribund mice or mice with severely compromised
health conditions were euthanized, and all major tissues were har-
vested and fixed in 10% formalin (soft tissues) or Bouin’s fixative
(bones). Tumors were identified and diagnosed by an experienced
veterinary pathologist (A.B.R.). Mice harboring no tumors were con-
sidered as censored subjects.
Focus Formation Assay and Image Analysis
Cells (53 104 or 13 105) were incubated with viral supernatants over-
night. After 2 or 3 weeks, cells were fixed in cold 100%methanol. Foci
were visualized by staining cells with 0.1% toluidine blue solution fol-
lowed by destaining with 1% acetic acid. Images were documented
with a FluorChem Imaging System (Alpha Innotech). The numbers
and sizes of foci were further measured using CellProfiler software.
Lentiviral shRNA Knockdown Experiment
Lentiviral pLKO.1-puro shRNA constructs were obtained from the
RNAi Consortium. Specific hairpin sequences and detailed viral pro-
duction procedures can be found in the Supplemental Data.
Cell Proliferation Assay
Cell number and mass were quantitated by DNA (Hoechst 33342) and
protein (sulforhodamine B) staining, respectively, using standard pro-
cedures. Detailed procedures are described in the Supplemental Data.
Cell Counting and Viability Assay
Cell number and viability were quantitated by microcapillary flow
cytometer (Guava EasyCyte System, Guava Technologies) using the
ViaCount reagent (Guava Technologies).
In-Cell Western
Cells were fixed with 10% formalin/PBS solution for 20min.Wells were
blocked with Odyssey blocking buffer (LI-COR Biosciences) for 2 hr at
RT and incubated with phospho-p44/42 MAPK (Thr202/Tyr204) Ab
(4377, Cell Signaling Technology) at 4Covernight. After washing, cells
were stained with IRDye 800CW Donkey Anti-Rabbit (LI-COR Biosci-
ences) and TO-PRO-3 iodide (Invitrogen) for 1 hr at RT. After washing,
microplates were scanned using the Odyssey Infrared imaging system
(LI-COR Biosciences).
PKA Activity Assay
PKA activity was measured with the PepTag Non-Radioactive cAMP-
Dependent Protein Kinase Assay kit (Promega).
Glucose Uptake Analysis
After incubation with medium containing 100 mM 2-NBDG (Invitrogen)
overnight, cells were washed with PBS and detached. The relative
fluorescence intensity of cells was measured using a Guava EasyCyte
cytometer, and histograms were plotted using WinMDI software.
Cell Survival Assay
Relative cell growth/survival was measured using the CellTiter-Blue
Cell Viability Assay Reagent (Promega).
Statistical Analysis
All statistical analyses were performed using Prism 4 (GraphPad Soft-
ware).CellSupplemental Data
Supplemental data include Supplemental Experimental Procedures,
nine figures, and one table and can be found with this article online
at http://www.cell.com/cgi/content/full/130/6/1005/DC1/.
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